ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.The journal of prevention of Alzheimer's disease · 2024Trial
- Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition.Brain : a journal of neurology · 2026Article
- A multiverse analysis of the logical memory test and plasma biomarkers of Alzheimer's disease.Cortex; a journal devoted to the study of the nervous system and behavior · 2026Article
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Association Between the Genetic Risk for Attention-Deficit/Hyperactivity Disorder and Cognitive Function in Older Age: The MYHAT Population-Based Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Article
- Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Substituting blood-based biomarkers for imaging measures in Alzheimer's disease studies: implications for sample size and bias.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Staging Alzheimer's disease through amyloid and tau PET.Brain : a journal of neurology · 2026Article
- The prognostic value of blood-based p-tau217 levels on progression to clinical impairment.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer's disease in individuals free of dementia.The Clinical neuropsychologist · 2026Article
- Predictive Value of Plasma Biomarkers in Tau-PET Transitions.Annals of neurology · 2025Article
- Sociodemographic correlates of cognition and Alzheimer's disease and vascular biomarkers among middle to older age participants in the Healthy Brain Initiative.Journal of Alzheimer's disease : JAD · 2025Article
- Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease.Journal of neurochemistry · 2025Article
- Substituting Blood-Based Biomarkers for Imaging Measures in Alzheimer's Disease Studies: Implications for Sample Size and Bias.medRxiv : the preprint server for health sciences · 2025Article
- Salivary mitochondrial DNA is associated with biomarkers of Alzheimer's disease in cognitively normal older adults.Translational psychiatry · 2025Article
- The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates.International journal of molecular sciences · 2025Review
- Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.The Lancet. Neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundWe compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals.
methodsWe studied 645 Mayo Clinic Study of Aging participants. Predictor variables were age, sex, education, apolipoprotein E (APOE) ε4 genotype, amyloid PET, and plasma amyloid beta (Aβ)42/40, phosphorylated tau (p-tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and p-tau217. The outcome was a change in a memory composite measure.
resultsAll plasma biomarkers, except NfL, were associated with mean memory decline in models with individual biomarkers. However, amyloid PET and plasma p-tau217, along with age, were key variables independently associated with mean memory decline in models combining all predictors. Confidence intervals were narrow for estimates of population mean prediction, but person-level prediction intervals were wide. DISCUSSION: Plasma p-tau217 and amyloid PET provide useful information about predicting rates of future cognitive decline in cognitively unimpaired individuals at the population mean level, but not at the individual person level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.